FDA Approves Nevirapine XR
On 25 March 2011, the FDA approved an extended release formulation of nevirapine XR (Viramune-XR) 400 mg extended release tablet.
The approval is based on one principal clinical trial (1100.1486) that demonstrated prolonged suppression of HIV-1 RNA through 48-weeks, and a supportive trial (1100.1526).
Based on serious and life-threatening hepatotoxicity observed in controlled and uncontrolled studies, nevirapine should not be initiated in adult females with CD4+ cell counts greater than 250 cells/mm3 or in adult males with CD4+ cell counts greater than 400 cells/mm3 unless the benefit outweighs the risk
The 14-day lead-in period with immediate-release nevirapine 200 mg daily dosing must be strictly followed; it has been demonstrated to reduce the frequency of rash.
If rash persists beyond the 14-day lead-in period with immediate-release nevirapine, do not begin dosing with nevirapine XR. The lead-in dosing with 200 mg once-daily should not be continued beyond 28 days, at which point an alternative regimen should be sought.
Filing in Europe for nevirapine XR has already taken place with a decision from the EMA expected in the third quarter of 2011.
Source: FDA list serve.
The complete product label will be posted at:
Links to external websites are current at time of posting but not maintained.
This article was provided by HIV i-Base. It is a part of the publication HIV Treatment Bulletin. Visit HIV i-Base's website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)